Boston Scientific Boosts EMEA Urology Revenues 28% with $3.3bn Axonics Deal and Valencia Additions
Boston Scientific's EMEA urology segment posted $682m in Q3 2025 revenue, up 28% year-over-year, driven by its $3.3bn Axonics acquisition and Valencia Technologies purchase. Treated patients in bladder and bowel dysfunction rose from one million to over three million with these additions, ahead of the Axonics F15 SNM system launch.
1. EMEA Urology Revenue Growth
In Q3 2025, Boston Scientific’s EMEA urology segment generated $682m in revenue, marking a 28% increase compared to Q3 2024.
2. Strategic Acquisitions Bolster Portfolio
The $3.3bn acquisition of Axonics in October 2024 and the recent purchase of Valencia Technologies have added sacral neuromodulation and implantable tibial nerve stimulation systems to its urology offerings, complementing its Bulkamid urethral bulking system.
3. Patient Reach Expands with New Therapies
With Axonics SNM and Valencia’s eCoin devices, the number of patients treated for bladder and bowel dysfunctions has grown from one million to over three million annually, positioning Boston Scientific ahead of the Axonics F15 SNM system launch.
4. Long-Term Market Prospects
The global neurological devices market value is projected to reach $20.9bn by 2033, up from $12.5bn in 2023, underlining growth potential for Boston Scientific’s expanded urology portfolio.